Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 15/20 | 1.00 |
| ▸ | GSK3B | P49841 | 15/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 11/20 | 0.82 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 0.82 |
| ▸ | FLT3 | P36888 | 6/20 | 0.74 |
| ▸ | STK17B | O94768 | 2/20 | 0.74 |
| ▸ | CDK1 | P06493 | 5/20 | 0.73 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.73 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.73 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.73 |
| ▸ | CDK4 | P11802 | 2/20 | 0.73 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.73 |
| ▸ | CCND1 | P24385 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | CDK14 | O94921 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30319807 | 0.90 | GSK3A (1.00) | GSK3AGSK3BCDK2CCNE1CDK5 | |
| SCHEMBL29975793 | 0.85 | GSK3A (1.00) | GSK3AGSK3BCDK2CCNE1CDK5 | |
| SCHEMBL29648491 | 0.85 | GSK3A (1.00) | GSK3AGSK3BCDK2CCNE1CDK5 | |
| SCHEMBL29421607 | 0.84 | GSK3A (1.00) | GSK3AGSK3BCDK2CCNE1CDK5 | |
| SCHEMBL30597665 | 0.82 | GSK3A (1.00) | GSK3AGSK3BCDK2CCNE1CDK5 | |
| SCHEMBL29961097 | 0.82 | GSK3A (1.00) | GSK3AGSK3BCDK2CCNE1CDK5 | |
| SCHEMBL30319809 | 0.80 | GSK3A (1.00) | GSK3AGSK3BCDK2CCNE1CDK5 | |
| SCHEMBL30597674 | 0.78 | GSK3A (1.00) | GSK3AGSK3BCDK2CCNE1CDK5 | |
| SCHEMBL30597679 | 0.78 | GSK3A (1.00) | GSK3AGSK3BCDK2CCNE1CDK5 | |
| SCHEMBL30094663 | 0.78 | GSK3A (1.00) | GSK3AGSK3BCDK2CCNE1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425457-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING METABOLIC DISEASES AND/OR A CLINICAL CONDITION THEREOF | CK BIOTECH INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| WO-2024233940-A1 | CELL REPLACEMENT THERAPY FOR PULMONARY DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-3866786-B1 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING METABOLIC DISEASES AND/OR A CLINICAL CONDITION THEREOF | CK REGEON INC (KR) | 2024-09-18 | — | — | EP | disclosed |
| CN-115969814-A | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | 法斯瑞斯公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-4142754-A1 | METHODS FOR GENERATING THYMIC CELLS IN VITRO | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425457-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING METABOLIC DISEASES AND/OR A CLINICAL CONDITION THEREOF | CBX6, CXXC5, PNLIP | GSK3A 755/4885GSK3B 669/4885CDK2 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.